The anti-mesothelin monoclonal antibody amatuximab enhances the anti-tumor effect of gemcitabine against mesothelin-high expressing pancreatic cancer cells in a peritoneal metastasis mouse model

SUPPLEMENTARY MATERIALS

Supplementary Figure 1: Time schedule of evaluation of the effect of amatuximab under an adjuvant setting in a peritoneal metastasis pancreatic cancer mouse model.

Supplementary Figure 2: Time schedule of combination therapy of GEM and amatuximab under an adjuvant setting in a peritoneal metastasis pancreatic cancer mouse model.